Special Issue "Adjuvant Therapy for Melanoma: Recent and Future Developments"
Deadline for manuscript submissions: 31 December 2021.
Interests: adjuvant therapy; melanoma; immunotherapy
Adjuvant therapy utilizing immune checkpoint blockades (anti-PD-1 Abs) and targeted therapies (BRAF/MEK inhibitors) against melanoma have been approved several years ago. Now these drugs are widely used in many countries. However, the real-world evidence of adjuvant therapy against melanoma is still lacking. For examples, response rates of the recurrent melanoma to the immune checkpoint blockades and targeted therapies are unknown. There is not enough evidence which therapies should be used firstly when the melanoma showed BRAF V600 mutation. Furthermore, neoadjuvant therapies are now tested its efficacy in many trials.
In this Special Issue: Adjuvant Therapy for Melanoma: Recent and Future Developments, the recent evidence of adjuvant therapy for melanoma will be reviewed. And new original research articles for the future developments of adjuvant therapy are going to be presented. Overall, we are confident that this Special Issue will be of interest to the broad readership of the journal. It will provide substantial information covering our current knowledge and future expectations on adjuvant therapy against melanoma.
Dr. Satoshi Fukushima
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Adjuvant Therapy
- Targeted therapy
- Neoadjuvant therapy